Accepted by several global regulatory authorities including the FDA and the European Pharmacopeia, the recombinant Factor C method is a recognized, comparable endotoxin detection method to LAL-based assays. USP 28-NF 33 General Notices states that alternative testing methods, such as recombinant Factor C (rFC) can be used if the alternative method provides advantages in accuracy, sensitivity, precision, selectivity, or adaptation to automation.
According to USP, the rFC assay is still considered an “Alternative Test”, subject to the validation requirements of USP <1225> or ICH Q2B. Regulatory authorities will accept the test results of the recombinant Factor C assay, but a validation study must be performed for each product that will be tested using this method. Validation studies are used to compare the alternative and compendial method, and verify the equivalence between the two methods of the assay. Post-validation, it is necessary to follow up with the appropriate regulatory filing for the drug product or device.
PyroGene® Validation Timeline
A possible validation scheme is outlined in the image on the left. The validation scheme is identical to that which would be needed for any LAL-based method with just the addition of one extra step, ”Validation of Alternative Method'.
We offer a full Validation Protocol that can be followed for your convenience. For further information, please submit your Validation Protocol Request or contact our Scientific Support Team for a free consultation with our Subject Matter Expert.